APYXAPYXHealthcare · Medical Devices

APYX Stock Forecast: Apyx Medical Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.40
+0.42% on the day

The 6 Wall Street analysts covering Apyx Medical Corp. hold a median 12-month price target of $6 — +150.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 76 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$101.1M
Ticker Nerd rank
76/ 100
Median analyst target
$6.00
Analysts covering
6
Revenue$13.9M+22.1% y/y
Operating income−$1.8M
Net income−$3.1M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.6%
1M
−1.6%
YTD
−31.4%
1Y
−40.6%
From 52W high
−50.6%
From 52W low
+1.7%
$2.36
$4.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Apyx Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
76/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
92
Growth
76
Quality
74
Value
57
Volatility
56
Momentum
54
Accruals
28
Issuance
27

Revisions (92): Analysts have, on balance, been raising their forecasts.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

APYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26APYXHigh $8.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$6.00
Low
$6.00
Median
$8.00
High

The green dot is the last close — the median target sits +150.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2026Maxim GroupInitiatesBuy$6.00
13 July 2026HC Wainwright & Co.InitiatesBuy$7.00
11 Mar 2026BTIGUpgradeBuy—
11 Mar 2026Craig-HallumMaintainsBuy—
16 Dec 2025Roth CapitalInitiatesBuy—
12 Nov 2025CitizensUpgradeMarket Outperform—
17 Oct 2024BTIGInitiatesNeutral—
16 Sept 2024JMP SecuritiesReiteratesMarket Perform—
10 Nov 2023Stephens & Co.MaintainsOverweight—
11 Aug 2023Piper SandlerMaintainsOverweight—
14 July 2023Stephens & Co.InitiatesOverweight—
15 June 2023Lake StreetMaintainsBuy—
24 May 2023JMP SecuritiesReiteratesMarket Perform—
12 May 2023Lake StreetMaintainsBuy—
8 Dec 2022Lake StreetAssumesBuy$5.00
12 Aug 2022Piper SandlerMaintainsOverweight—
19 July 2022Lake StreetMaintainsBuy—
20 May 2022Lake StreetInitiatesBuy—
13 Aug 2021JMP SecuritiesMaintainsMarket Outperform—
12 May 2020JMP SecuritiesMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for APYX.

Market Radar

This page is one stock. Monday covers all of them.

APYX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

APYX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Apyx Medical Corp. returned −40.6% against +6.9% for the S&P 500, dividends included.

APYX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26APYXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.7×

Cheaper than 53% of US stocks

Price / book
10.5×

Cheaper than 7% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
63.9%

Higher than 77% of US stocks

Operating margin
−5.5%

Higher than 29% of US stocks

Net margin
−14.2%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−102.5%

Higher than 13% of US stocks

Return on assets
−3.4%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Apyx Medical Corp. has a market value of $101.1M and an enterprise value of $115.5M.

  • Revenue in the twelve months to 30 June 2026: $58.4M. The latest quarter grew 22.1% year on year.

  • Net income over the same four quarters: −$8.4M, a −14.4% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.20.

  • Free cash flow in the twelve months to 30 June 2026: −$11.0M.

  • Shares outstanding: 42.1M.

  • Apyx Medical Corp. employs 205 people — $285K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

APYX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
APYXApyx Medical Corp.$101.1M76
STIMNeuronetics, Inc.$95.2M64
QTRXQuanterix Corp.$92.3M53
LUNGPulmonx Corp.$111.9M87
CATXPerspective Therapeutics, Inc.$91.0M11
OWLTOwlet, Inc.$85.0M27
LUCDLucid Diagnostics, Inc.$75.7M36

Take a look at APYX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Apyx Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about APYX

What is the APYX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Apyx Medical Corp. have a median 12-month price target of $6, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APYX stock a buy right now?

Of the 6 analysts covering Apyx Medical Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apyx Medical Corp. 76 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APYX?

As at 21 Nov 2026, Apyx Medical Corp. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).

Will APYX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +150.0% from the last close, and Ticker Nerd's factor model ranks Apyx Medical Corp. 76 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APYX stock forecast for 2030?

No analyst covering Apyx Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.

How has APYX stock performed over the past year?

Apyx Medical Corp. returned -40.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apyx Medical Corp. do?

Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures.

Company

About Apyx Medical Corp.

Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures. Its products are used by physicians, surgery centers, hospitals, and other healthcare providers across surgical aesthetics and broader electrosurgical applications. Apyx Medical Corporation also serves original equipment manufacturing customers with engineered medical devices and components. Headquartered in Clearwater, Florida, Apyx Medical Corporation focuses on tools that combine energy delivery and surgical performance for modern operating environments.

CEO Mr. Charles D. Goodwin II · 205 employees · United States · https://apyxmedical.com